{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:53:09Z","timestamp":1752673989092},"reference-count":30,"publisher":"Japan Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1507\/endocrj.ej23-0005","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T22:13:38Z","timestamp":1686176018000},"page":"797-804","source":"Crossref","is-referenced-by-count":2,"title":["Copeptin is associated with microalbuminuria and renal function in the general Japanese population"],"prefix":"10.1507","volume":"70","author":[{"given":"Aya","family":"Nakae","sequence":"first","affiliation":[{"name":"Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto 602-8566, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Ozaki","sequence":"additional","affiliation":[{"name":"Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto 602-8566, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagato","family":"Kuriyama","sequence":"additional","affiliation":[{"name":"Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto 602-8566, Japan"},{"name":"Shizuoka Graduate University of Public Health, Shizuoka 420-0881, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Tomida","sequence":"additional","affiliation":[{"name":"Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto 602-8566, Japan"},{"name":"Department of Endocrine and Breast Surgery, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto 602-8566, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhide","family":"Koyama","sequence":"additional","affiliation":[{"name":"Department of Epidemiology for Community Health and Medicine, Kyoto Prefectural University of Medicine Graduate School of Medical Science, Kyoto 602-8566, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, et al. (2016) Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis. PLoS One 11: e0158765.","DOI":"10.1371\/journal.pone.0158765"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296\u20131305.","DOI":"10.1056\/NEJMoa041031"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Clark WF, Sontrop JM, Huang SH, Moist L, Bouby N, et al. (2016) Hydration and chronic kidney disease progression: a critical review of the evidence. Am J Nephrol 43: 281\u2013292.","DOI":"10.1159\/000445959"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Strippoli GF, Craig JC, Rochtchina E, Flood VM, Wang JJ, et al. (2011) Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton) 16: 326\u2013334.","DOI":"10.1111\/j.1440-1797.2010.01415.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Sontrop JM, Dixon SN, Garg AX, Buendia-Jimenez I, Dohein O, et al. (2013) Association between water intake, chronic kidney disease, and cardiovascular disease: a cross-sectional analysis of NHANES data. Am J Nephrol 37: 434\u2013442.","DOI":"10.1159\/000350377"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Handler JS, Orloff J (1981) Antidiuretic hormone. Annu Rev Physiol 43: 611\u2013624.","DOI":"10.1146\/annurev.ph.43.030181.003143"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kishore BK, Mandon B, Oza NB, DiGiovanni SR, Coleman RA, et al. (1996) Rat renal arcade segment expresses vasopressin-regulated water channel and vasopressin V2 receptor. J Clin Invest 97: 2763\u20132771.","DOI":"10.1172\/JCI118731"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52: 112\u2013119.","DOI":"10.1373\/clinchem.2005.060038"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, et al. (2010) Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 77: 29\u201336.","DOI":"10.1038\/ki.2009.397"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Golembiewska E, Machowska A, Stenvinkel P, Lindholm B (2017) Prognostic value of copeptin in chronic kidney disease: from general population to end-stage renal disease. Curr Protein Pept Sci 18: 1232\u20131243.","DOI":"10.2174\/1389203718666170717095301"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Tasevska I, Enh\u00f6rning S, Christensson A, Persson M, Nilsson PM, et al. (2016) Increased levels of copeptin, a surrogate marker of arginine vasopressin, are associated with an increased risk of chronic kidney disease in a general population. Am J Nephrol 44: 22\u201328.","DOI":"10.1159\/000447522"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Boertien WE, Riphagen IJ, Drion I, Alkhalaf A, Bakker SJ, et al. (2013) Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33). Diabetologia 56: 1680\u20131688.","DOI":"10.1007\/s00125-013-2922-0"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13 Velho G, Bouby N, Hadjadj S, Matallah N, Mohammedi K, et al. (2013) Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria. Diabetes Care 36: 3639-3645.","DOI":"10.2337\/dc13-0683"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, et al. (2011) Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 6: 361\u2013368.","DOI":"10.2215\/CJN.04560510"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nakajima A, Lu Y, Kawano H, Horie S, Muto S (2015) Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD). Clin Exp Nephrol 19: 1199\u20131205.","DOI":"10.1007\/s10157-015-1101-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Wakai K, Hamajima N, Okada R, Naito M, Morita E, et al. (2011) Profile of participants and genotype distributions of 108 polymorphisms in a cross-sectional study of associations of genotypes with lifestyle and clinical factors: a project in the Japan Multi-Institutional Collaborative Cohort (J\u2013MICC) Study. J Epidemiol 21: 223\u2013235.","DOI":"10.2188\/jea.JE20110072"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ando S, Koyama T, Kuriyama N, Ozaki E, Uehara R (2020) The association of daily physical activity behaviors with visceral fat. Obes Res Clin Pract 14: 531\u2013535.","DOI":"10.1016\/j.orcp.2020.10.004"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, et al. (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982\u2013992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B (2009) Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 42: 725\u2013728.","DOI":"10.1016\/j.clinbiochem.2009.01.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Roussel R, Matallah N, Bouby N, El Boustany R, Potier L, et al. (2015) Plasma copeptin and decline in renal function in a cohort from the community: the prospective D.E.S.I.R. study. Am J Nephrol 42: 107\u2013114.","DOI":"10.1159\/000439061"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, et al. (2009) Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 116: 257\u2013263.","DOI":"10.1042\/CS20080140"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Burckhardt MA, Wellmann M, Fouzas S, Lapaire O, Burkhardt T, et al. (2014) Sexual disparity of copeptin in healthy newborn infants. J Clin Endocrinol Metab 99: E1750\u2013E1753.","DOI":"10.1210\/jc.2014-2244"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Perucca J, Bouby N, Valeix P, Bankir L (2007) Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 292: R700\u2013R705.","DOI":"10.1152\/ajpregu.00500.2006"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Bankir L, Bouby N, Ritz E (2013) Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 9: 223\u2013239.","DOI":"10.1038\/nrneph.2013.22"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Bardoux P, Bichet DG, Martin H, Gallois Y, Marre M, et al. (2003) Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 18: 497\u2013506.","DOI":"10.1093\/ndt\/18.3.497"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Blair HA (2019) Tolvaptan: a review in autosomal dominant polycystic kidney disease. Drugs 79: 303\u2013313.","DOI":"10.1007\/s40265-019-1056-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, et al. (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407\u20132418.","DOI":"10.1056\/NEJMoa1205511"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323\u20131326.","DOI":"10.1038\/nm935"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Bouby N, Bachmann S, Bichet D, Bankir L (1990) Effect of water intake on the progression of chronic renal failure in the 5\/6 nephrectomized rat. Am J Physiol 258: F973\u2013F979.","DOI":"10.1152\/ajprenal.1990.258.4.F973"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Clark WF, Sontrop JM, Macnab JJ, Suri RS, Moist L, et al. (2011) Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 6: 2634\u20132641.","DOI":"10.2215\/CJN.01990211"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/8\/70_EJ23-0005\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:48:43Z","timestamp":1715575723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/8\/70_EJ23-0005\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej23-0005","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"EJ23-0005"}}